SBIR Phase I: Identifying Toxicity Pathways

这个小企业创新研究（SBIR）第一阶段项目旨在开发一种技术，以提高对药物如何改变细胞过程的理解。随着HTP技术的发展，可以获得基因表达、蛋白质和代谢产物的谱，以帮助阐明产生特定表型的途径网络。该项目将开发一种方法，揭示被改变的途径，并将有助于选择具有最高疗效和最小毒性的候选药物。开发新药变得越来越昂贵，具有挑战性和昂贵，不仅在财政资源方面，而且在毒性方面。通过在药物发现过程的早期识别，具有成为成功疗法的最高可能性的候选化合物将降低开发成本;伴随着公共卫生保健成本的降低。

This Small Business Innovative Research (SBIR) Phase I project aims to develop a technology to improve the understanding of how drugs alter cellular processes. With advance in HTP technology, profiles of gene expressions, proteins and metabolites can be acquired to help elucidate the network of pathways involved in producing a specific phenotype. The project will develop a methodology that reveals the pathways that are altered and will facilitated the selection of drug candidates with the highest efficacy and minimal toxicity.Developing new drugs has become increasingly expensive, challenging and costly, not only in term of financial resources but also in toxicity. By identifying early in the drug discovery process, candidate compound with the highest probabilities of becoming successful therapies will reduce the cost of development; with the concomitant reductions in public health care costs.